Efficacy and Safety of EsoDuo®
Launched by CHONG KUN DANG PHARMACEUTICAL · May 21, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called EsoDuo® to see how well it works in controlling symptoms of gastroesophageal reflux disease (GERD), such as heartburn. The trial is currently looking for participants aged 19 and older who have been diagnosed with non-erosive reflux disease or mild erosive reflux disease and have experienced episodes of heartburn. However, if you have had certain esophageal conditions, recent cancer, or specific surgeries, you may not be eligible to join.
If you participate in this trial, you can expect to take EsoDuo® and report on your symptoms over a set period. The goal is to determine how effective and safe the medication is for managing reflux symptoms. This study is open to both men and women, and it aims to help improve treatment options for people suffering from GERD. Your involvement could contribute to valuable research that may benefit others facing similar health issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male or Female aged ≥ 19 years
- • 2. Patients diagnosed with non-erosive reflux disease or mild erosive reflux disease
- • 3. Episode of heartburn the GERD symptom(either heartburn or gastric acid reflux)
- Exclusion Criteria:
- • 1. Surgery history on stomach or esophagus
- • 2. Barrett's esophagus (over 3cm), esophageal varices, esophageal stricture, esophageal achalasia, eosinophilic esophagitis, and primary motility disorders
- • 3. Patients diagnosed with Grade C or Grade D according to the LA Classification system during upper gastrointestinal endoscopy
- • 4. Patients with a history of malignancy within the past 5 years prior to the screening visit (Visit 1)
- • 5. Patients who have taken prohibited concomitant medications within 14 days prior to the screening visit or require continuous administration of prohibited medications during the trial period.
- • 6. Clinically significant Abnormal Lab test
- • 7. Pregnant woman, Breastfeeding woman.
About Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical is a leading South Korean pharmaceutical company dedicated to the research, development, manufacturing, and marketing of innovative healthcare solutions. With a strong emphasis on quality and efficacy, the company specializes in a diverse range of therapeutic areas, including oncology, cardiology, and neurology. Chong Kun Dang is committed to advancing patient care through clinical trials that adhere to the highest ethical standards, leveraging cutting-edge technology and scientific expertise to bring new treatments to market. Its robust pipeline and collaborative approach position the company as a key player in the global pharmaceutical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Hwoon-Yong Jung, M.D, PhD
Principal Investigator
Asan Medical Cental of Korea
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported